Sarepta Therapeutics Inc (NASDAQ:SRPT) shares traded down 6.2% during trading on Thursday . The stock traded as low as $57.13 and last traded at $57.17. 1,162,212 shares changed hands during mid-day trading, a decline of 34% from the average session volume of 1,771,082 shares. The stock had previously closed at $60.95.

Several research analysts recently commented on the company. Barclays reaffirmed a “hold” rating and issued a $55.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, January 23rd. William Blair reissued an “outperform” rating on shares of Sarepta Therapeutics in a report on Monday, February 5th. Royal Bank of Canada assumed coverage on Sarepta Therapeutics in a report on Monday, January 22nd. They set an “outperform” rating for the company. Leerink Swann reissued an “outperform” rating and set a $77.00 price objective on shares of Sarepta Therapeutics in a report on Friday, January 19th. Finally, Zacks Investment Research raised Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. One analyst has rated the stock with a sell rating, six have assigned a hold rating and seventeen have issued a buy rating to the stock. Sarepta Therapeutics currently has a consensus rating of “Buy” and an average target price of $64.65.

The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $3,440.00, a PE ratio of -27.03 and a beta of 1.49.

In related news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $55.89, for a total value of $372,618.63. Following the completion of the sale, the director now directly owns 13,333 shares in the company, valued at $745,181.37. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 9.60% of the stock is owned by company insiders.

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its position in Sarepta Therapeutics by 0.9% in the fourth quarter. BlackRock Inc. now owns 6,286,343 shares of the biotechnology company’s stock worth $349,773,000 after purchasing an additional 58,433 shares during the period. Vanguard Group Inc. increased its position in Sarepta Therapeutics by 4.0% in the second quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock worth $143,572,000 after purchasing an additional 162,543 shares during the period. Jennison Associates LLC grew its position in shares of Sarepta Therapeutics by 0.6% during the 4th quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock worth $63,998,000 after buying an additional 6,357 shares during the period. Eagle Asset Management Inc. grew its position in shares of Sarepta Therapeutics by 26.0% during the 3rd quarter. Eagle Asset Management Inc. now owns 1,006,222 shares of the biotechnology company’s stock worth $49,858,000 after buying an additional 207,810 shares during the period. Finally, Emerald Advisers Inc. PA grew its position in shares of Sarepta Therapeutics by 2.1% during the 3rd quarter. Emerald Advisers Inc. PA now owns 893,484 shares of the biotechnology company’s stock worth $40,528,000 after buying an additional 18,077 shares during the period. Hedge funds and other institutional investors own 81.97% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Sarepta Therapeutics (SRPT) Stock Price Down 6.2%” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.watchlistnews.com/sarepta-therapeutics-srpt-stock-price-down-6-2/1858109.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.